Results 1 to 10 of about 169,757 (284)
Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish [PDF]
Haematologica, 2012 Background Chromosomal translocations resulting in alternative fusions of the human TEL (ETV6) and JAK2 genes have been observed in cases of acute lymphoblastic leukemia and chronic myelogenous leukemia, but a full understanding of their role in disease ...
Sara M. N. Onnebo +4 more
doaj +4 more sources
Chronic myelogenous leukemia on target [PDF]
Cancer Medicine, 2018 Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro‐leukemic activity of the BCR‐ABL1 oncoprotein.
Veronika Némethová, Filip Rázga
doaj +4 more sources
Haematologica, 2013 Second generation tyrosine kinase inhibitors have recently been introduced as first-line treatment for chronic phase chronic myelogenous leukemia. We aimed to evaluate the efficacy and safety of 2nd generation tyrosine kinase inhibitors versus imatinib ...
Ronit Gurion +9 more
doaj +2 more sources
Nature Communications, 2021 Resistance to tyrosine kinase inhibitors (TKI) is a limitation to their use in treating chronic myelogenous leukemia (CML). Here, the authors show that targeting the ubiquitin peptidase USP47 overcomes TKI resistance and eliminates leukaemia stem ...
Hu Lei +21 more
doaj +2 more sources
Haematologica, 2013 The BCR-ABL T315I mutation confers resistance to currently licensed tyrosine kinase inhibitors in chronic myelogenous leukemia. However, the impact of this mutation on survival in early stages of disease, in chronic phase, has never been detailed.
Franck E. Nicolini +24 more
doaj +2 more sources
Pathogenesis of chronic myelogenous leukemia
Haematologica, 1994 n ...
G Bergamaschi, V Rosti
doaj +4 more sources
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients [PDF]
Blood, 1990 Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with interferon alpha and transfusion of viable donor buffy coat.
H-J Kolb +7 more
semanticscholar +3 more sources
A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib [PDF]
Clinical Case Reports, 2022 Patients with chronic myelogenous leukemia (CML) harboring the T315I mutation who progress to blast phase CML while on ponatinib may be successfully treated with asciminib monotherapy following induction therapy with cytotoxic chemotherapy.
Sarah Tomassetti, Jennifer Lee, Xin Qing
doaj +2 more sources
BMC Complementary and Alternative Medicine, 2012 Background In this report, the isorhamnetin 3-o-robinobioside and its original extract, the ethyl acetate extract, from Nitraria retusa leaves, were evaluated for their ability to induce antioxidant and antigenotoxic effects in human chronic myelogenous ...
Boubaker Jihed +4 more
doaj +2 more sources
A label free chemoproteomic-based platform to disclose cannabidiol molecular mechanism of action on chronic myelogenous leukemia cancer cells [PDF]
HeliyonThe discovery of the interactome of cannabidiol (CBD), a non-psychoactive cannabinoid from Cannabis sativa L., has been here performed on chronic myelogenous leukemia cancer cells, using an optimized chemo-proteomic stage, which links Drug Affinity ...
Sara Ceccacci +8 more
doaj +1 more source